BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was downgraded by investment analysts at William Blair from an “outperform” rating to a “market perform” rating in a research ...

Biomarin Pharmaceutical (NASDAQ:BMRN) is preparing to release its quarterly earnings on Tuesday, 2024-10-29. Here's a brief overview of what investors should keep in mind before the announcement.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on BioMarin (BMRN) to $109 from $110 and keeps an Overweight rating on the shares post the Q3 report. The firm sees an attractive ...

We recently published a list of 10 Best Falling Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target dropped by equities research analysts at Citigroup from $93.00 to $81.00 in a research report issued on Wednesday, Benzinga ...

Blue Trust Inc. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 504.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 859 shares ...

BioMarin Pharmaceutical BMRN reported adjusted earnings per share of 91 cents in third-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. Quarterly earnings rose 98% year over year ...

State of Alaska Department of Revenue cut its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 19.4% during the third quarter, according to the company in its ...

DekaBank Deutsche Girozentrale cut its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor ...